Navigation Links
Gene therapy could expand stem cells' promise
Date:5/21/2009

Once placed into a patient's body, stem cells intended to treat or cure a disease could end up wreaking havoc simply because they are no longer under the control of the clinician.

But gene therapy has the potential to solve this problem, according to a perspective article from physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center published in a recent issue of the journal Cell Stem Cell. The paper details strategies for genetically modifying stem cells prior to transplantation in order to ensure their safety.

"Stem cell therapy offers enormous potential to treat and even cure serious diseases. But wayward stem cells can turn into a runaway train without a conductor. This is an issue that can be dealt with and we have the technology to do that in the form of gene therapy," says senior author Dr. Ronald G. Crystal, chief of the Division of Pulmonary and Critical Care Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and the Bruce Webster Professor of Internal Medicine and Professor of Genetic Medicine at Weill Cornell Medical College.

Stem cells have the capacity to differentiate into any of the different tissues making up the human body, thus holding the promise of treating or curing diseases such as multiple sclerosis or spinal-cord injury by replacing diseased cells with healthy cells.

But unlike other therapies such as chemotherapy, antibiotics or aspirin, stem cells have no expiration date, and that poses a real problem.

"Almost all therapeutics we use have a half life. They only last a certain amount of time," Dr. Crystal says. "Stem cells are the opposite. Once the future stem cell therapist does the therapy, stem cells have the innate potential to produce more cells."

The challenge takes on even more urgency with recent developments, including a federal administration now more open to exploring the potential of stem cells, the recent FDA appro
'/>"/>

Contact: John Rodgers
jdr2001@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2

Related biology news :

1. Breakthrough in radiotherapy promises targeted cancer treatment
2. From cars to cancer: UH professor employs auto industry tools for tumor therapy
3. Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy
4. Moving gene therapy forward with mobile DNA
5. Simulated gene therapy
6. Early administration of antiretroviral therapy can improve survival
7. Stem cell therapy makes cloudy corneas clear, according to Pitt researchers
8. Gene therapy appears safe to regenerate gum tissue
9. Two-day symposium in Baltimore to tackle the promises and perils of proton radiotherapy
10. CSHL team develops mouse models of leukemia that predict response to chemotherapy
11. Taste, odor intervention improves cancer therapy, according to Virginia Tech, Wake Forest study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... neurodegenerative diseases, such as mad cow disease or its ... infectious protein called a prion. Remarkably, in recent years ... roles in biology, and prions even may act as ... But although prions have received a great deal of ...
... responsible for genital warts was on target at the halfway ... Frazer and trial manager, sexual health specialist Dr David Jardine ... have taken part in the trial so far run from ... has so far proven safe, and we want to know ...
... Bae, Ph.D., Postdoctoral Research Associate in the Baumann ... the way cells protect chromosome ends from misguided ... Molecular Cell, their paper entitled "A RAP1/TRF2 Complex ... Ends" employed a biochemical assay for double-strand break ...
Cached Biology News:Scientists identify prion's infectious secret 2Scientists identify prion's infectious secret 3Baumann Lab defines proteins that distinguish chromosome ends from DNA double-strand breaks 2
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... Convey Computer , the leader in hybrid-core ... University won first place in the 2014 MemoCODE ... team’s solution achieved the highest overall performance in the ... finisher. , Experts from all segments of the commercial ... using a variety of design tools, hardware and software. ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... BioMed Realty Trust, Inc.,(NYSE: BMR ) ... underwriter,exercised its over-allotment option in full to purchase ... with BioMed,s previously,announced offering that priced on October ... of common stock, raising net proceeds of,approximately $212.4 ...
... a new dietary supplement resulting from years of, study by ... ... Del-Immune V, BOULDER, Colo., Oct. 6 On Thursday, October ... V(R) induction and its impact on cytotoxicity of,natural killer cells" will be ...
... European authority on natural/ organic certification -, ... /PRNewswire-FirstCall/ - Botaneco Specialty Ingredients,Inc. (Botaneco), a subsidiary ... second generation oleosome product, Hydresia(TM) G2, has,been authorized ... with,the standards for ecological and organic cosmetics. ECOCERT(R) ...
Cached Biology Technology:BioMed Realty Trust Announces Exercise of Over-Allotment Option 2BioMed Realty Trust Announces Exercise of Over-Allotment Option 3EUPROBIO 2008 Presentation to Highlight Latest Immune Research 2Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 2Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 3
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
... Pierce ready-to-use 2-D gel marker mix was designed ... gel marker mix contains a complement of seven ... of value to those who use markers to ... molecular weight values of proteins undergoing 2-D separation ...
... Tetrad 2 thermal cycler is a completely ... Tetrad chassis, and it accepts the full ... delivers the same precision in thermal performance ... Tetrad thermal cyclers, allowing easy transport of ...
... Engine Tetrad thermal cycler expands the ... PTC-200 DNA Engine cycler. ... with a footprint only twice the ... laboratories that run massive quantities of ...
Biology Products: